

Resource Summary Report

Generated by [NIF](#) on Sep 16, 2026

DB

RRID:CVCL_1168

Type: Cell Line

Proper Citation

RRID:CVCL_1168

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1168

Proper Citation: RRID:CVCL_1168

Description: Cell line DB is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Diffuse large B-cell lymphoma germinal center B-cell type

Defining Citation: [PMID:2313723](#), [PMID:19358282](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20628145](#), [PMID:20889926](#), [PMID:22460905](#), [PMID:23699601](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:26727417](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29416618](#), [PMID:29666304](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: DB

Cross References: CLO:CLO_0002709, EFO:EFO_0002158, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2289, BioSample:SAMN03471088, BioSample:SAMN10987903, cancercellines:CVCL_1168, Cell_Model_Passport:SIDM00886, ChEMBL-Cells:ChEMBL3308866, ChEMBL-Targets:ChEMBL2366331, CLS:305048, Cosmic:687839, Cosmic:906832,

Cosmic:1329087, Cosmic:1517658, Cosmic:1541916, Cosmic:1629928, Cosmic:1636692, Cosmic:1661883, Cosmic:1714157, Cosmic:2276321, Cosmic-CLP:906832, DepMap:ACH-000334, DSMZ:ACC-539, DSMZCellDive:ACC-539, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:906832, GEO:GSM274839, GEO:GSM552401, GEO:GSM562823, GEO:GSM886975, GEO:GSM888044, GEO:GSM1035321, GEO:GSM1105703, GEO:GSM1669727, GEO:GSM3150243, IARC_TP53:21299, IGRhCellID:DB, LiGeA:CCLE_212, LINCS_LDP:LCL-1119, PharmacDB:DB_284_2019, PRIDE:PXD012087, PRIDE:PXD030304, Progenetix:CVCL_1168, PubChem_Cell_line:CVCL_1168, Wikidata:Q54828581

ID: CVCL_1168

Record Creation Time: 20220427T215744+0000

Record Last Update: 20260913T002908+0000

Ratings and Alerts

No rating or validation information has been found for DB.

No alerts have been found for DB.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell, 44(7), 1437.

Demel UM, et al. (2026) Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(17), e11449.

Shi X, et al. (2025) NFS1, together with FXN, protects cells from ferroptosis and DNA damage in diffuse large B-cell lymphoma. Redox biology, 87, 103878.

L????nd F, et al. (2025) DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. Blood cancer discovery, 6(6), 580.

Cai HM, et al. (2025) DDX3X mutation and Epstein-Barr virus cooperate to induce R-loop-dependent oncogenesis. Cell reports, 44(9), 116237.

Li Y, et al. (2024) USP19 exerts a tumor-promoting role in diffuse large B cell lymphoma through stabilizing PARK7. *The FEBS journal*, 291(21), 4757.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell chemical biology*, 31(7), 1247.

Eiken AP, et al. (2024) Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects. *Cancer research communications*, 4(5), 1328.

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. *Blood cancer discovery*, 5(6), 417.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. *Cancer research communications*, 3(4), 576.

Portelinha A, et al. (2021) ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. *Cell reports. Medicine*, 2(7), 100350.

Dersh D, et al. (2021) Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. *Immunity*, 54(1), 116.

Potjewyd F, et al. (2020) Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degradar. *Cell chemical biology*, 27(1), 47.

Brescia P, et al. (2018) MEF2B Instructs Germinal Center Development and Acts as an Oncogene in B Cell Lymphomagenesis. *Cancer cell*, 34(3), 453.